Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Controlled drugs

Give pharmacy the resources needed to tackle stubbornly high drug abuse rates

A street drug-testing pilot scheme in Somerset suggests that pharmacists could have a massive impact on reducing illicit drug use, but this work will go no further if funding is not found.

small drug bags cast big shadow next to warning sign

Source: JL / The Pharmaceutical Journal

Government figures show that over a one-year period around 1 in 11 adults (aged 16–59 years) used an illicit drug in England and Wales. This equates to around 3 million people. For young people (aged 16–24 years), this proportion more than doubles to around one in five. And, despite huge efforts to reduce illicit drug use, there has been little change in these figures over the past decade.

This failure to tackle the problem has consequences. The most recent statistics show that there were 3,756 deaths from drug poisoning in England and Wales in 2017, with two-thirds of these related to misuse of illicit drugs. Pushing illicit substances to the margins is clearly not working and so a new approach is needed.

If people are not going to stop taking these substances, then one way to reduce the level of harm they can cause is to provide users with information on what they may be taking

A new pharmacist-led street drug-testing service in Somerset, south-west England — the first to be licensed by the Home Office — may provide a different way forward.

If people are not going to stop taking these substances, one way to reduce the level of harm they can cause is to provide users with information on what they may be taking. This outreach service, which recently reached the end of its month-long trial, tested samples of illicit substances in real time, offering users advice on the drugs they held, and, where appropriate, brief clinical interventions. 

The pilot scheme was operated by the charity Addaction, along with the University of Hertfordshire and The Loop, a non-profit drug testing organisation. The full results of the testing period are yet to be published, but the pharmacists behind it are satisfied that their ‘proof-of-concept’ operation has been a success.

The team told The Pharmaceutical Journal that, despite its short run time, the pilot project analysed a wider-than-expected variety of drugs, brought in across a diverse demographic and saw people with different types of substance misuse histories and drug-taking habits. Some of the drug users were already known to the local drug service, but they also saw recreational drug users who may otherwise not have come into contact with any kind of drug treatment facility.

Some people who used the service said they had changed their drug-taking habits as a result. Others said the brief interventions delivered by staff may have had more of an impact because of the immediate knowledge of what they were intending to take.

Acceptance of the scheme, both by illicit drug users and the general public, was helped by the prominent involvement of pharmacists. This provided a level of trust, those involved say, and also improved the service’s accessibility.

This is only a small pilot, housed in a relatively little-used drug service, so its benefits should not be overstated and the evidence must be published before hard decisions can be made. But those running this service say there has been keen interest in their work within the UK and internationally, and the potential gains could be great if it was replicated in larger towns or cities. 

However, local authorities are already having to slash their substance abuse provision as a result of cuts to public health funding — the think tank The Health Foundation estimates there has been a reduction of £900m in funding, in real terms, for public health between 2014/2015 and 2019/2020 in England. This is only made worse by the soaring cost of buprenorphine, which led to local authorities and charities spending £5.5bn on its inflated price concession in 2018. As a result, finding the money to provide such a novel service elsewhere may be a struggle.

Momentum for pharmacists to be given greater scope to employ their clinical skills is building, following the publication of the ‘NHS Long Term Plan’ in January 2019 in England and other intiatives in the devolved nations. The placement of pharmacists in GP surgeries, A&E departments and care homes across the UK and pharmacy negotiators’ hopes of securing a landmark community pharmacy contract in England to reward case management of patients shows what a difference pharmacists can make.

But this pilot potentially shows that pharmacists could have a powerful role in improving public health, using their expert knowledge to reduce harm for drug users and lessening the burden on the NHS. It must be hoped that, somehow, the money can be found to take such an innovative, progressive and valuable pharmacist-led service forward and tackle this intractable problem.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206374

Readers' comments (1)

  • Pharmacists have long been recognised as valuable contributors to drug treatment services. With the advent of new drugs of abuse including so called “legal highs” and prescription medicines recently classified as CDs the need to do more is accelerating. I remember the vast over prescribing of benzodiazepines and see it emerging again with pregabalin and gabapentin. This initiative is brilliant but so much more can be done if pharmacists were true shared care partners practicing autonomously as part of a larger team. The new contract talks are essential to unlock this potential but drug treatment services have always been funded by public health and the home office as well as the NHS. It’s vital that such bodies are consulted and convinced now or we will get the continued decline we are witnessing and pilots such as this will continue to gather dust in the vaults of good intention.

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.